Navigation Links
Odyssey Thera to Participate in Expanded EPA Initiative
Date:12/6/2010

SAN RAMON, Calif., Dec. 6, 2010 /PRNewswire/ -- The United States Environmental Protection Agency (EPA) announced today a new phase of toxicity screening, in which 1,000 chemicals will be screened as part of EPA's ToxCast initiative. Odyssey Thera's participation in this program, first announced earlier this year, involves the application of extensive and diverse proprietary assay and screening technologies. "The Odyssey team is very pleased with our contributions to ToxCast to date, and we're excited to see this program accelerating," said Dr. Jane E. Lamerdin, Executive Director of R&D at Odyssey Thera, "ToxCast represents an ideal application of our validated chemical analysis strategies."

The chemicals will be assessed for potential toxicity to people and the environment. ToxCast is designed to determine how chemical exposures impact human biological processes and how the chemicals most likely lead to health effects. When fully implemented, ToxCast will be able to screen thousands of chemicals in fast, cost-effective tests that are relevant to human health. The chemicals being tested are found in industrial and consumer products, food additives and drugs that never made it to the market.

The full news release can be found at: http://yosemite.epa.gov/opa/admpress.nsf/d0cf6618525a9efb85257359003fb69d/73ec2518e34bc93d852577eb0060dd7c!OpenDocument. More information on ToxCast and the list of chemicals can be found at http://www.epa.gov/comptox.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a privately held drug discovery technology company focused on improving the success rate of new therapeutic development. Odyssey Thera's technology measures disease–relevant pathway activity within living human cells. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical and biotechnology company partners. Patents owned by Odyssey also cover the use of the technology in live animals, plants and for diagnostic and bioprocess applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
2. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
3. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
4. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
5. Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy
6. Halozyme Therapeutics Realigns Management
7. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
8. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
9. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
10. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
11. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter and year-end 2015 results after the Nasdaq market ... host a live conference call and webcast to discuss ... afternoon, February 11, 2016 at 4:30 p.m. Eastern Time ... --> http://www.neurocrine.com . --> Participants can ...
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 ... addition of the "Global Skin Protective Equipment ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... ( http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition of ...
(Date:2/8/2016)... Intarcia Therapeutics, Inc. today announced the appointment of ... created role of Vice President, Head of Global Medical ... of leadership experience at leading pharmaceutical, biotechnology, and health ... Most recently Dr. Yee served as VP, Head of ... Officer at AstraZeneca, where he led medical affairs across ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... Nevada (PRWEB) , ... February 08, 2016 , ... ... RowdMap, Inc., will be speaking on how healthcare companies can use newly released ... manage the health of a population and intervene and capture the value they ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
Breaking Medicine News(10 mins):